Menu
Search
|

Menu

Close
X

Altimmune Inc ALT.OQ (NASDAQ Stock Exchange Global Market)

2.25 USD
+0.10 (+4.65%)
As of Sep 13
Previous Close 2.15
Open 2.17
Volume 13,714
3m Avg Volume 47,810
Today’s High 2.25
Today’s Low 2.17
52 Week High 36.25
52 Week Low 1.70
Shares Outstanding (mil) 13.45
Market Capitalization (mil) 31.61
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY19
3
FY18
10
FY17
11
FY16
3
EPS (USD)
FY19
-0.269
FY18
-22.683
FY17
-108.991
FY16
-35.571
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
2.98
7.90
Price to Book (MRQ)
vs sector
0.53
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
3.62
17.64
LT Debt to Equity (MRQ)
vs sector
2.84
12.61
Return on Investment (TTM)
vs sector
-64.89
12.69
Return on Equity (TTM)
vs sector
-80.04
17.13

EXECUTIVE LEADERSHIP

Mitchel Sayare
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Vipin Garg
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
William Brown
Chief Financial Officer, Principal Accounting Officer, Since 2019
Salary: --
Bonus: --
M. Scot Roberts
Chief Scientific Officer, Since 2017
Salary: --
Bonus: --
David Drutz
Independent Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

910 Clopper Rd Ste 201S
GAITHERSBURG   MD   20878-1361

Phone: +1240.6541450

Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.

SPONSORED STORIES